2 weeks Ago By Defense World Staff
PolyPid ( NASDAQ:PYPD – Get Free Report ) will be announcing its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter.
Investors interested in participating in the company’s conference call can do so using this link . PolyPid ( NASDAQ:PYPD – Get Free Report ) last released its earnings results on Wednesday, August 14th. The company reported ($1.
25) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.26.
On average, analysts expect PolyPid to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year. PolyPid Price Performance PYPD stock opened at $3.54 on Tuesday.
The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.
95. PolyPid has a 52 week low of $2.95 and a 52 week high of $9.
20. The firm’s fifty day moving average is $3.47 and its 200 day moving average is $3.
84. The firm has a market cap of $16.99 million, a P/E ratio of -0.
35 and a beta of 1.31. Analyst Ratings Changes View Our Latest Analysis on PolyPid PolyPid Company Profile ( Get Free Report ) PolyPid Ltd.
, a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. Featured Stories Five stocks we like better than PolyPid What is the Euro STOXX 50 Index? 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion How to Invest in Blue Chip Stocks Monday.
com’s Manic Price Pullback Is a Signal to Buy What is MarketRankTM? How to Use it 3 “Made in America” Stocks to Benefit From the Trump Presidency Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter ..
